Hikal DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.58×	0.62×	0.73×	0.73×	0.74×
	−0.89×	−1.38×	0.64×	0.64×	0.71×
	3.8%	3.3%	10.4%	8.4%	7.3%
	0.70×	0.70×	0.74×	0.73×	0.88×
	1.97×	1.97×	2.00×	2.09×	2.10×
	−2.7%	−3.9%	7.2%	6.0%	7.2%
	−4.0%	−4.0%	7.4%	6.0%	7.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HIKAL₹193.01

Hikal Limited

· Pharma & Health

₹ CrorePeersPANACEABIO DCAL SAIPARENT INDOCO SOLARA WINDLAS INDSWFTLAB HESTERBIOMcap ₹2,384 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.73	0.73	0.62	0.58
Interest Burden (Pretax/EBIT) ×	0.71	0.64	0.64	-1.38	-0.89
EBIT Margin %	7.32	8.37	10.43	3.30	3.76
Asset Turnover ×	0.88	0.73	0.74	0.70	0.70
Financial Leverage (Assets/Equity) ×	2.10	2.09	2.00	1.97	1.97
ROE (5-step product, year-end total equity) %	7.18	5.96	7.24	-3.94	-2.69
ROE (owners' profit / average owners' equity) %	7.12	6.00	7.41	-3.97	-3.97

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.